Transformative Lung Cancer Screening at Penn Highlands Healthcare
Lung cancer remains a leading cause of cancer mortality in the U.S., surpassing breast, colon, and prostate cancers combined. Thanks to a groundbreaking screening initiative at Penn Highlands Healthcare, many individuals diagnosed with lung cancer are experiencing longer, healthier lives. The Lung Center has pioneered early detection through its comprehensive screening program.
Introduction of Advanced Screening Technology
Penn Highlands Healthcare, renowned for its commitment to patient care, became a designated Center of Excellence with GO2 for Lung Cancer. It was the first in its region to implement a low-dose CT lung screening program designed to uncover cancerous lung nodules effectively. In a significant advancement, the center is now employing artificial intelligence (AI) to identify potential cancerous nodules even when they appear as incidental findings in imaging reports.
Significance of Early Detection
Dr. Sandeep Bansal, the Medical Director of The Lung Center, emphasizes the critical change in lung cancer diagnostics over the past decade. Remarkably, about 75% of lung cancers detected through their low-dose CT screening program are diagnosed at Stage 1 or 2. This early detection significantly increases treatment success rates, highlighting the importance of regular screenings, especially for at-risk populations.
Identifying High-Risk Individuals
The screening program primarily targets individuals aged 50 to 80 who have a significant smoking history, including those with 20 pack-years of smoking. Statistics indicate that around 87% of lung cancer cases stem from smoking, with the remaining 13% attributed to factors like genetics and environmental influences.
Understanding the Screening Process
When a nodule is detected during a low-dose CT scan, its characteristics are analyzed to determine the likelihood of cancer. This evaluation includes factors like the nodule's size and the patient’s smoking history. Patients are categorized into three risk levels based on these assessments:
Low Risk
For patients classified as low risk, follow-up occurs every three to six months over a span of up to two years. Dr. Bansal notes that the primary objective of this process is to maintain close communication with the patients' primary care physicians to guarantee they receive appropriate ongoing care.
Intermediate Risk
Approximately 65% of lung nodules fall into this category. Most of these patients will undergo a biopsy, often through a minimally invasive procedure called robotic bronchoscopy. This method, introduced in 2019, uses a robotic arm to assist in obtaining lung tissue samples and provides a less invasive option for diagnosis.
High Risk
Patients classified as high risk may require surgical intervention to remove nodules and stage the cancer. For lung cancer that is diagnosed at later stages, such as 3 or 4, chemotherapy and radiation treatments become necessary.
Leveraging AI for Enhanced Detection
The Lung Center at Penn Highlands Healthcare is now integrating cutting-edge AI technology from Eon, a leader in intelligent healthcare, to further boost early lung cancer detection. This AI software enhances the identification of potential cancerous nodules by extracting key terminology from radiology reports and highlighting subtle abnormalities that may otherwise be overlooked.
Recognition of Excellence
Recently, the center was honored with the Eon Center of Excellence Gold Award, acknowledging its diligent follow-up on incidental lung nodules. This recognition underscores the facility's ability to provide exceptional patient care through timely and accurate surveillance practices.
Results of the Partnership with Eon
Since the collaboration began, more than 5,500 lung nodules have been identified through enhanced screening methods. Notably, patients with nodules larger than 8 mm show a remarkable follow-up return rate of 93.2%—far exceeding the industry benchmarks.
Supportive Care Team at The Lung Center
The dedication of the team at The Lung Center is instrumental in patient care. Physicians and nurse practitioners work alongside skilled navigators—like Candace Cole, Savannah Shirley, and Amber Witherow—who support patients throughout their treatment journeys. These navigators act as vital advocates, ensuring patients receive the guidance needed from initial screenings through any required treatments.
Importance of Patient Advocates
Dr. Bansal highlights the crucial role that navigators play in the cancer care process, serving as a dedicated point of contact who assists patients at every step of their journey through treatment.
Conclusion
Penn Highlands Healthcare was established in 2011 and is composed of nine hospitals, with a mission to provide quality healthcare across the region. With a workforce of about 6,200 employees and facilities spread across 26 counties, the health system is determined to continue enhancing care options for individuals and families.
Frequently Asked Questions
What is the significance of early lung cancer detection?
Early detection of lung cancer greatly enhances treatment success rates and improves survival outcomes.
What technologies does the Lung Center use for screening?
The Lung Center uses low-dose CT scans and advanced AI technology to identify lung nodules.
Who is eligible for screening at Penn Highlands Healthcare?
Individuals aged 50 to 80 with significant smoking history are primarily eligible for lung screenings.
What happens if a nodule is found during screening?
If a nodule is detected, it will be assessed for cancer probability, followed by appropriate follow-up actions depending on the risk classification.
How does the support team assist patients?
The support team includes navigators who provide guidance and advocacy throughout the patient's healthcare journey, ensuring they receive necessary resources and care.
